The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Finkelstein, David I
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. [electronic resource] - Acta neuropathologica communications 06 2017 - 53 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2051-5960
10.1186/s40478-017-0456-2 doi
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Animals
Antiparkinson Agents--pharmacology
Cation Transport Proteins--metabolism
Cell Line, Tumor
Dogs
Female
Humans
Iron--metabolism
Male
Mice, Inbred C57BL
Mice, Transgenic
Neurons--drug effects
Neuroprotective Agents--pharmacology
Oxidative Stress--drug effects
Oxidopamine
Parkinsonian Disorders--drug therapy
Quinazolinones--pharmacology
Rats
Recombinant Proteins--genetics
Substantia Nigra--drug effects
alpha-Synuclein--genetics
Ferroportin
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. [electronic resource] - Acta neuropathologica communications 06 2017 - 53 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2051-5960
10.1186/s40478-017-0456-2 doi
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Animals
Antiparkinson Agents--pharmacology
Cation Transport Proteins--metabolism
Cell Line, Tumor
Dogs
Female
Humans
Iron--metabolism
Male
Mice, Inbred C57BL
Mice, Transgenic
Neurons--drug effects
Neuroprotective Agents--pharmacology
Oxidative Stress--drug effects
Oxidopamine
Parkinsonian Disorders--drug therapy
Quinazolinones--pharmacology
Rats
Recombinant Proteins--genetics
Substantia Nigra--drug effects
alpha-Synuclein--genetics
Ferroportin